Summary The prognostic value of Ki-67 immunohistochemical labelling was evaluated in 327 operable primary carcinomas of the breast. The follow-up time was up to 4 years (mean 2.7 years). The disease-free survival in Ki-67 positive patients was shorter than in Ki-67 negative patients (P<0.005). By combining the Ki-67 expression with ER receptors and stage, subgroups with a different disease-free survival were identified. In stage II patients there was a significant difference (P <0.005) in disease-free survival between Ki-67 positive/ER negative and Ki-67 negative/ER positive patients. In node negative patients there was no such difference. The disease-free survival according to different prognostic factors, stage, ER and node status, were separately examined using a Cox's proportional hazards model. ER (P <0.0001), the Ki-67 (P <0.02), tumour size (P<0.0001) and nodal status (P<0.006) were independent prognostic factors. We conclude that the potential value of Ki-67 labelling for prognostic evaluation of patients with breast carcinoma is good.
The increasing number of options for the treatment of breast carcinoma has made the prognostic evaluation of the disease even more important. The histologic criteria for grading of the carcinoma into poorly differentiated and well differentiated ones was established already in 1957 (Bloom & Richardson, 1957) . Patients with poorly differentiated tumours have a shorter relapse-free survival than those with differentiated ones. Node positivity also decreases the disease-free survival time (Du-Toit et al., 1990; Fisher et al., 1983) . Methods of 3H Thymidine incorporation (Silvestrini et al., 1974) and flow cytometry (Kallioniemi et al., 1987) are well established but complex procedures giving prognostic information. It is desirable to find easier methods for the prognostic evaluation of breast carcinoma. In this respect the introduction of a mouse monoclonal antibody Ki-67 by Gerdes et al. (1983) simplified the measurement of proliferative activity in breast carcinoma tissue. The monoclonal antibody labels a still unknown nuclear antigen in proliferating cells. Cell nuclei in the resting stage (GO) are not stained. Ki-67 immunoreactivity has been studied in several types of carcinoma, e.g. in breast carcinoma (Barnard et al., 1987; Gasparini et al., 1992; Locker et al., 1992) , in bladder carcinoma (Fontana et al., 1992) , in carcinoma of the prostate (Thompson et al., 1992) and in colon carcinoma (Porschen et al., 1991) All 327 breast carcinomas were stained for Ki-67, and 281 tumours were also successfully stained for ER. The cut-off points for the Ki-67 and ER grading were arbitrarily chosen at the beginning of the study before the outcome of the carcinoma was known. The Ki-67 was graded as follows: Ki-67 negative: at the most, rare nuclear staining. weakly positive (+): about 1-2% nuclear staining. moderately positive (+ + ): 3-10% nuclear staining. strongly positive ( + + + ) > 10% nuclei stained. For the ER grade determination, ER up to 10% was scored as negative, 10-40% weakly positive, 40-70% moderately positive and over 70% strongly positive. The percentage of Ki-67 and ER positive cells was estimated by the same pathologist at the time of the operation from at least five randomly chosen medium power microscopic fields containing at least 2,000 cells. The Ki-67 was also independently scored by a biologist without knowledge of the outcome of the disease or of the score assessed by the primary observer. Metastatic disease was confirmed by radiological and clinical examination.
Ki-67 status was correlated to other prognostic factors: ER content, stage, tumour differentiation and nodal status. The relationship between disease-free survival and Ki-67 status, p-TNM, ER content and stage was also analysed.
Statistical methods
The disease-free survival was determined using a life table analysis with a product limit method on all patients. The correlation analysis was done with the logrank-chi-square method. Multivariate analysis including p-TNM, and immunohistochemical determination of ER and Ki-67 was performed by the Cox's proportional hazards model.
Results
Most tumours were ductal carcinomas (78%). Forty-one percent were stage I and 49% were stage II carcinomas. A breast resection was done in 46% of the patients with stage I and in 15% of those with stage II carcinomas. The overall resection rate was 61%. Most patients (137) were followed up to 3 years and 72 patients up to 4 years. The mean follow-up time was 2.7 years.
The disease-free survival (DFS) was significantly longer in node negative than in node positive patients (P <0.005) (Figure la) , and the same applied to oestrogen receptor (ER) positive vs negative patients (P < 0.005) (Figure l b) . The DFS decreased with increasing stage (P<0.025) (Figure ic (Table I) . The overall patient survival according to Ki-67 expression showed no significant differences between the different Ki-67 groups (Figure 2a) . On the other hand, there was a difference in the disease-free survival between Ki-67 negative and strongly positives (+ + +) (x2 = 17.3, P<0.005) (Figure 2b ). There was no difference in the Ki-67 results obtained by the two independent observers. The correlation with DFS was the same. There were only small differences in the scores (Figure 3) .
Neither the distribution of the Ki-67 expression according to the stage, nor the distribution of Ki-67 expression within the different groups of oestrogen expression showed any significant differences (data not shown). Likewise, the distribution of the Ki-67 expression according to the nodal status did not show statistically significant differences (data not shown). The histologic grading of the specimens was not done routinely, but to evaluate the correlation between Ki-67 and grade, a randomly chosen group of 40 specimens was graded. There was a positive correlation between Ki-67 labelling and tumour grade (P = 0.007).
If the patients were divided into groups according to the Ki-67 and ER expression to form different subgroups with potentially different risks (Figure 4) , patients with Ki-67 positive and ER negative tumours had the shortest DFS (P <0.05). Patients with Ki-67 negative and ER positive tumours had the longest DFS. The DFS was also significantly shorter for Ki-67 positive and ER positive tumours as compared to Ki-67 negative and ER positive tumours ( Figure  4) .
In an attempt to identify those stage I patients with poor prognosis, the stage I patients with ER negative and Ki-67 positive tumours were compared with those with ER positive and Ki-67 negative tumours. The difference in DFS between these groups was not significant, probably due to a too short follow-up time. On the other hand, in stage II tumours there was a significant difference in the disease-free survival when 
Discussion
Because of the short follow-up period of the patients we chose to focus on the disease-free survival. Our study suggests that determination of the proliferative activity of breast carcinoma by immunohistochemical staining with the monoclonal antibody Ki-67 provides a useful prognostic indicator fo the relapse-free period in patients with breast carcinoma. The data suggest that if Ki-67 labelling is used alone as a prognostic factor a useful cut-off point delineating a high-risk group is 10% labelling nuclei, that is 'strongly positive' in our study. We found that patients with Ki-67 positive, ER negative tumours had a clearly shorter disease-free survival than other combinations of these two parameters, and it may be relevant to routinely combine the results of these two analyses in the pathologist's report. The histologic grading of the tumours in this series also showed a positive correlation to Ki-67 labelling (P = 0.007) in agreement with previous reports (Barnard et al., 1987; Gasparini et al., 1992; Locker et al., 1992; Weikel et al., 1991) . From a practical point of view, one of the most important goals is to identify stage I patients with a poor risk (about 10% of the total) who might benefit from some type of adjuvant therapy. We failed to distinguish a subgroup of such poor risk patients in stage I (ER negative/Ki-67 positive), perhaps because of the small number of patients and the relatively short follow-up time of a maximum of 4 years. Neither has it been possible to single out those node negative patients, which will get a relapse using the EGFR expression, which is closely linked to cell proliferation activity (Toi et al., 1991) . Similar results for early relapses in node negative patients have been obtained with her/neu oncogene (Slamon & Clark, 1988) . Cathepsin D has also failed to predict disease-free survival in node negative patients, while its predictive value was considerably strengthened when combined with ER-determinations (Granata et al., 1991) . Long term follow-up studies on stage I and node negative patients show that a recurrence can occur decades after the initial diagnosis. Those new methods which cannot be applied to fixed archivel tissue still need some time to show their value. In stage II tumours, including also node negative patients, there was a significant difference in disease free survival between Ki-67 positive/ER negative and ER positive/Ki-67 negative (P <0.005). O'Reilly has described an even more specific subdivision of patients with different prognosis using the S-phase fraction (SPF) and tumour size (O'Reilly et al., 1990 ). According to these results patients with tumour greater than 1 cm with an SPF < 10% have a 5-year relapse-free survival of 78%, compared to 52% in tumours of the same size with an SPF> 10%. The higher prognostic value of SPF compared to Ki-67 might be due to the longer follow up time (median 8 years). The SPF value is also higher in aneuploid tumours than in diploid tumours (O'Reilly, et al., 1990) which might give SPF a better discriminatory power than Ki-67. On the other hand, the Ki-67 scores are much higher in aneuploid carcinomas than in diploid ones (Gasparini et al., 1991) .
In conclusion, despite the relatively short follow-up period of this study, our data suggest the potential value of Ki-67 labelling as a relatively simple and inexpensive method for prognostic evaluation of patients with breast carcinoma. The value of the method is enhanced if the result in the pathologist's report is given in conjunction with the immunohistochemical evaluation of oestrogen receptors. Until recently the study of Ki-67 proliferation antigen has been restricted to such cases, where fresh or frozen tissue is available. Recently new antibodies have been developed which also detect the Ki-67 antigen in paraffin embedded tissues (Cattoretti et al., 1992) .
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